These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21946274)

  • 41. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
    Serra V; Eichhorn PJ; García-García C; Ibrahim YH; Prudkin L; Sánchez G; Rodríguez O; Antón P; Parra JL; Marlow S; Scaltriti M; Pérez-Garcia J; Prat A; Arribas J; Hahn WC; Kim SY; Baselga J
    J Clin Invest; 2013 Jun; 123(6):2551-63. PubMed ID: 23635776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.
    Muranen T; Selfors LM; Worster DT; Iwanicki MP; Song L; Morales FC; Gao S; Mills GB; Brugge JS
    Cancer Cell; 2012 Feb; 21(2):227-39. PubMed ID: 22340595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
    Ghayad SE; Cohen PA
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.
    Li J; Xiao Q; Bao Y; Wang W; Goh J; Wang P; Yu Q
    Cell Cycle; 2019 Jul; 18(13):1513-1522. PubMed ID: 31135266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
    Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G
    Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
    Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
    PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
    Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.